Track Cardio Diagnostics Holdings Inc. Common stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cardio Diagnostics Holdings Inc. Common stock CDIO · Stock Open Cardio Diagnostics Holdings Inc. Common stock in new tab

1.92 USD
Add to portfolio
EPS
-2.82
P/B
0.75
ROE
-75.44
Beta
2.23
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateNov. 6, 2026
EPS-2.82
Book Value2.51
Price to Book0.75
Debt/Equity4.98
% Insiders8.307%
Growth
Revenue Growth-0.28%
Estimates
Forward P/E-7.58
Forward EPS-0.25

DCF Valuation

Tweak assumptions to recompute fair value for Cardio Diagnostics Holdings Inc. Common stock (CDIO)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Cardio Diagnostics Holdings Inc. Common stock Logo Cardio Diagnostics Holdings Inc. Common stock Analysis (CDIO)

United States Health Care Official Website Stock

Is Cardio Diagnostics Holdings Inc. Common stock a good investment? Cardio Diagnostics Holdings Inc. Common stock (CDIO) is currently trading at 1.92 USD.

Earnings Schedule: Cardio Diagnostics Holdings Inc. Common stock is expected to release its next earnings report on Nov. 6, 2026. The market consensus estimate for Forward EPS is -0.25.

Investor FAQ

Does Cardio Diagnostics Holdings Inc. Common stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cardio Diagnostics Holdings Inc. Common stock?

Cardio Diagnostics Holdings Inc. Common stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 6, 2026. The company currently has a trailing EPS of -2.82.

Company Profile

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Exchange Ticker
NMS (United States) CDIO
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
May 13, 2025 0.03
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion